Close Menu

Celera Genomics’ bioinformatics subsidiary Paracel quietly threw in the towel last week, posting a notice on its website that it had ceased operations — except for ongoing support for its current customers — as of Sept. 28.

The closure brought an end to several years of uncertainty about the business unit’s role within Celera after the genomics giant reinvented itself as a drug discovery shop in mid-2002.

“The decision to close Paracel was made following an analysis of various alternatives for the business,” Celera noted in a statement on its website.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.